摘要
脑卒中是常见的脑血管病,具有发病率高、致残率高、病死率高的特点。氯吡格雷是经典的抗血小板药物,其可有效预防脑卒中复发,亦是不能行溶栓治疗脑卒中患者的有效治疗药物,但部分患者不能从氯吡格雷临床应用中获益,出现氯吡格雷抵抗(CR)现象。CR的发生会影响氯吡格雷对脑卒中的治疗效果,严重者甚至会发生不良临床事件。CYP2C19基因多态性是影响CR发生最重要的内部因素,其可影响机体内氯吡格雷的代谢,进而影响其抗血小板作用。因此,CYP2C19基因多态性与CR的关系仍是未来的研究重点。
Stroke is a common cerebrovascular disease with high incidence,high disability rate and high mortality.Clopidogrel is a classic antiplatelet drug that can effectively prevent stroke recurrence and is also an effective treatment for stroke patients who cannot undergo thrombolytic therapy.However,some patients cannot benefit from the clinical application of clopidogrel,due to the phenomenon of clopidogrel resistance(CR).The occurrence of CR can affect the therapeutic effect of clopidogrel on stroke,and in severe cases,adverse clinical events may even occur.The CYP2C19 gene polymorphism is the most important internal factor affecting the occurrence of CR,which can affect the metabolism of clopidogrel in the body,thereby affecting its antiplatelet effect.Therefore,the relationship between CYP2C19 gene polymorphism and CR remains a focus of the future research.
作者
钟宇
李恺
刘义
ZHONG Yu;LI Kai;LIU Yi(Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs,School of Pharmacy,Guangdong Medical University,Dongguan 523808,China;Pharmacy Intravenous Admixture Service,Meizhou People′s Hospital,Meizhou 514000,China)
出处
《医学综述》
CAS
2024年第1期13-18,共6页
Medical Recapitulate